650-274-8199
Quick Selection.png
Visit
  • Twitter - White Circle
  • LinkedIn - White Circle
©2019 BY NEUCYTE, INC.

World Preclinical Congress

June 17-20, 2019. Boston, MA

wpc-logo.png

Meet Us at WPC2019 and See How NeuCyte can Help Accelerate Your CNS Drug Discovery,

Efficacy and Safety Assessment

Booth 233

Join our scientific presentations 

Beyond iPSC Based Disease Models:

A Translatable Drug Discovery Platform for Status Epilepticus

Epilepsy is a common neurological disorder characterized by recurrent spontaneous seizures. About 30% of patients do not respond or develop resistance to available anti-epileptic drug treatments. The establishment of more translatable human cell-based assays can address the unmet need for new therapy strategies by complementing pre-clinical drug development to increase success rates in human patients. NeuCyte has built an iPSC-derived neural in vitro platform with complex electrophysiology-based phenotypic readouts to evaluate the efficacy of novel compounds and approved AEDs for the treatment of Status Epilepticus.

Date: June 18th

Time: 2:10pm

Room: Cityview 1

Daniel Haag, PhD

CSO and Co-Founder, NeuCyte

Overcoming Challenges in CNS Drug Discovery through Developing Translatable iPSC-derived Cell-Based Assays

 Using direct reprogramming of iPSCs to generate defined human neural tissue, NeuCyte developed cell-based assays with complex neuronal structure and function readouts for versatile pre-clinical applications. Focusing on electrophysiological measurements, we demonstrate the capability of this approach to identify adverse neuroactive effects, evaluate compound efficacy, and serve phenotypic drug discovery.

Date: June 20th

Time: 1:00pm

Room: Harborview 1

Jonathan Dávila, PhD

CTO and Co-Founder, NeuCyte

View our Scientific Poster

Implementation of Human iPSC-derived Neural Cultures in CNS Drug Discovery

June 18-20